Lee H K, Driscoll D, Asch H, Asch B, Zhang P J
Department of Pathology and Laboratory Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA.
Prostate. 1999 Jun 15;40(1):14-9. doi: 10.1002/(sici)1097-0045(19990615)40:1<14::aid-pros2>3.0.co;2-6.
Because of its role in cell motility and growth regulation, gelsolin, an actin-binding protein, has been considered a tumor suppressor and a potential prognostic marker in some neoplasias, such as breast and bladder cancer. Little is known about its immunoexpression in prostatic adenocarcinoma (PCA).
Formalin-fixed, paraffin-embedded tissues of 72 prostatectomy specimens with adenocarcinoma and 8 nonneoplastic prostates from autopsies were stained with a gelsolin monoclonal antibody using the Avidin-biotin-peroxidase complex (ABC) method after microwave antigen retrieval. Immunoreactivity was evaluated in PCA, prostatic intraepithelial neoplasia (PIN), benign prostatic hyperplasia (BPH), and nonproliferative glandular tissue and stroma. The results were statistically analyzed.
Consistent gelsolin immunoreactivity was seen in prostatic stromal cells, smooth muscle, endothelia, and nerves. Variable gelsolin expression was seen in 20-100% (average (A) = 65.5%) of glandular cells in nonproliferative tissue (N = 75); 0-50% (A = 9.7%) in BPH (N = 59); 0-80% (A = 8.9%) in PIN (N = 61); and 0-90% (A = 9.3%) in PCA (N = 71). The level of gelsolin expression in nonproliferative prostatic tissue was similar between prostates with PCA (A = 63.4%) and nonneoplastic prostates (A = 67.5%). The level of gelsolin expression did not correlate with age, tumor size, Gleason score, or stage.
Gelsolin is decreased in PCA, PIN, and BPH in comparison to nonproliferative tissue. The role of this downregulation in the development of PCA is not clear. The similar reduction seen in PIN and BPH suggests that this event takes place indiscriminately in hyperplasia and early tumorigenesis in the prostate, which might limit its prognostic significance in PCA.
凝溶胶蛋白作为一种肌动蛋白结合蛋白，因其在细胞运动和生长调节中的作用，在某些肿瘤（如乳腺癌和膀胱癌）中被视为肿瘤抑制因子和潜在的预后标志物。关于其在前列腺腺癌（PCA）中的免疫表达情况，人们了解甚少。
对72例前列腺癌根治术标本的福尔马林固定、石蜡包埋组织以及8例尸检获得的非肿瘤性前列腺组织，采用微波抗原修复后，运用抗生物素蛋白-生物素-过氧化物酶复合物（ABC）法，用凝溶胶蛋白单克隆抗体进行染色。对PCA、前列腺上皮内瘤变（PIN）、良性前列腺增生（BPH）以及非增殖性腺组织和基质中的免疫反应性进行评估。对结果进行统计学分析。
在前列腺基质细胞、平滑肌、内皮细胞和神经中可见一致的凝溶胶蛋白免疫反应性。在非增殖性组织（N = 75）中，20% - 100%（平均（A）= 65.5%）的腺细胞有可变的凝溶胶蛋白表达；在BPH（N = 59）中为0% - 50%（A = 9.7%）；在PIN（N = 61）中为0% - 80%（A = 8.9%）；在PCA（N = 71）中为0% - 90%（A = 9.3%）。有PCA的前列腺组织中，非增殖性前列腺组织的凝溶胶蛋白表达水平（A = 63.4%）与非肿瘤性前列腺组织（A = 67.5%）相似。凝溶胶蛋白表达水平与年龄、肿瘤大小、Gleason评分或分期无关。
与非增殖性组织相比，PCA、PIN和BPH中的凝溶胶蛋白减少。这种下调在PCA发生发展中的作用尚不清楚。PIN和BPH中出现的类似减少表明，这一事件在前列腺增生和早期肿瘤发生过程中无差别地发生，这可能会限制其在PCA中的预后意义。
